ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2675

Has the Relationship Between Disease Activity and Disability in Rheumatoid Arthritis Changed?

Aneela Mian1, Fowzia Ibrahim2,3, Ian C. Scott4, Sardar Bahadur5, Maria Filkova6, Louise Pollard7, Gabrielle H. Kingsley8, Sophia Steer9, David L. Scott6 and James Galloway10, 1Academic Rheumatology, King's College London, London, United Kingdom, 2Academic Rheumatology Dept, King's College, London, United Kingdom, 3Academic Rheumatology Dept, King's College London, London, United Kingdom, 4Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, 5Guys' and St Thomas' NHS Trust, London, United Kingdom, 6Academic Department of Rheumatology, King´s College London, London, United Kingdom, 7University Hospital Lewisham, London, United Kingdom, 8Rheumatology, Kings College London, London, United Kingdom, 9Rheumatology Dept, Kings College Hospital, London, United Kingdom, 10King's College Hospital, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disability and rheumatoid arthritis (RA), Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) management paradigms have changed over the last two decades. Evidence now supports aggressive immunosuppression with early use of combination disease modifying anti rheumatic drugs (DMARDs) and biologics when standard DMARDs fail. The use of composite tools to measure disease activity has become standard assessment tools in the clinic with an aim of achieving remission or low disease activity. We set out to study the changing patterns of disease activity and disability in RA over the last 20 years. 

Methods: Retrospective cross-sectional surveys were undertaken at four time points from two secondary care rheumatology departments in London. Patients included had a diagnosis of RA by the 1987 criteria of the American College of Rheumatology. The surveys collected data between (i) 1996-97; (ii) 2001-3; (iii) 2009-10; (iv) 2012-14. Data collected comprised demographic details (age, sex and disease duration), 28 joint disease activity score (DAS28) and its component parts. Disability measures  using the Health Assessment Questionnaire (HAQ) scores were also available for the first, second and fourth cohorts. 

Results: Overall 1324 patients were studied. The groups had similar demographic features (76-80% were female; their mean ages were 58-60 years; and their mean disease durations were 9.1-10 years. Disease activity fell over time, with the proportion of patients in remission significantly increasing from 8% in the earliest cohort to 28% in the most recent. The proportion with severe disease fell from 50% in the earliest cohort to 18% in the most recent, whilst the proportion with moderate disease remained constant (38-42%). Although the number of swollen joints has decreased in each DAS28 group over time, the more objective tender joint counts and patient global scores have increased or remained stable. In contrast, there was no fall in disability levels over time. Mean HAQ scores were 1.30 in 1996-97 and 1.32 in 2012-14, with a slightly higher mean HAQ of 1.52 in 2001-03. Comparing disability change over time across the disease activity groups, mean HAQ scores in patients in remission and low disease activity states increased. The correlation between disease activity and disability became weaker over time; in 1996-97 Spearman’s rho was 0.56, in 2001-03 it was 0.55 and in 2012-14 it was 0.44.

Conclusion: Our data add to the existing evidence base, confirming that the trends towards milder disease are continuing. There is a widening gap between the subjective and objective components of DAS, with climbing tender joint counts in the face of reduced numbers of swollen joints. Other factors such as comorbidity including psychological disease, may be very relevant. Depression and anxiety are highly prevalent in RA. Our data show that the relationship between disease activity and disability has changed over time. Further research is needed to understand how to best manage non-severe RA, that now makes up the largest burden of clinic attenders. Strategies to address comorbidity and mental health needs should to be evaluated.


Disclosure: A. Mian, None; F. Ibrahim, None; I. C. Scott, None; S. Bahadur, None; M. Filkova, None; L. Pollard, None; G. H. Kingsley, None; S. Steer, None; D. L. Scott, None; J. Galloway, None.

To cite this abstract in AMA style:

Mian A, Ibrahim F, Scott IC, Bahadur S, Filkova M, Pollard L, Kingsley GH, Steer S, Scott DL, Galloway J. Has the Relationship Between Disease Activity and Disability in Rheumatoid Arthritis Changed? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/has-the-relationship-between-disease-activity-and-disability-in-rheumatoid-arthritis-changed/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/has-the-relationship-between-disease-activity-and-disability-in-rheumatoid-arthritis-changed/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology